An investigation into the efficacy of a cognitive behavioural therapy group for low self-esteem in a primary care setting

2018 ◽  
Vol 11 ◽  
Author(s):  
Sarah Beattie ◽  
David Beattie
Keyword(s):  
Primary Care ◽  
Cognitive Behavioural Therapy ◽  
Care Setting ◽  
Primary Care Setting ◽  
Therapy Group ◽  
Self Esteem ◽  
Behavioural Therapy ◽  
Cognitive Behavioural ◽  
Mood Group ◽  
Group Programme

AbstractSelf-esteem refers to how an individual appraises themselves and is associated with good mental health. A number of studies have identified the efficacy of cognitive behavioural therapy (CBT) in the treatment of low self-esteem based on the formulation and treatment trajectory developed by Fennell (1999). However, there has been little empirical enquiry into the efficacy of the programme delivered in primary care. The current study investigated the effectiveness of a CBT programme for low self-esteem delivered within primary care. Fifty-four participants attended a 9-week ‘Boost Your Mood’ group programme. Paired sample t-tests were conducted on pre- and post-group scores on measures of depression, anxiety and self-esteem. Results indicated that there were statistically significant improvements in levels of depression, anxiety and self-esteem post-treatment. Findings are consistent with the suggestion that group CBT may be effective at increasing levels of self-esteem and reducing levels of depression and anxiety when delivered in a primary care setting.

scholarly journals The Effect of Brief Cognitive Behavioural Therapy Group Intervention on Self Esteem among Drug Users

2018 ◽  
Vol 150 ◽  
pp. 05092
Author(s):  
Huzilil Hussin ◽  
M.H. Othman ◽  
Kamarudin Hussin ◽  
N. S. Alias
Keyword(s):  
Cognitive Behavioural Therapy ◽  
Internal Control ◽  
Group Intervention ◽  
Drug Users ◽  
Therapy Group ◽  
Self Esteem ◽  
Behavioural Therapy ◽  
Control Group ◽  
Time Interval ◽  
Cognitive Behavioural

Self-esteem is related to the individuals understanding and accepting the existing character and attitude to themselves. Failure to understand and accept their own strengths and weaknesses and in the same time do not have the skills to cope with it will caused them to be classified in the group who have low levels of self esteem. The up and down in self esteem will seriously affect the person emotional development and their reasoning process. Thus, reforming self esteem is an important key to help the rehabilition of drug abuser. Therefore, the purpose of this study is to investigate the effects of Brief Group Cognitive Behavioural Therapy on self-esteem among drug users. The quasi experimental design with one treatment group and one control group and four measurements (Pre Test, Post 1, Post 2 and Post 3) were employed in this study. The sample of 108 drugs users was chosen using purposive sampling procedure. Data were collected using standardized psychometric instruments, including Internal Control Index (Patricia Duttweiler, 1984) and The Rosenberg Self-Esteem Scale and were analysed using descriptive analysis. The findings shows the intervention of group Brief Cognitive Behavioural Therapy CBT (B) are succeed in increasing self-esteem mean score compared to control group in different time interval. As a conclusion, self-esteem among the subjects can be enhanced with an intervention of proper and systematic therapy instead of unplanned therapy sessions

scholarly journals Group cognitive-behavioural therapy for schizophrenia

2006 ◽  
Vol 189 (6) ◽  
pp. 527-532 ◽  
Author(s):  
Christine Barrowclough ◽  
Gillian Haddock ◽  
Fiona Lobban ◽  
Steve Jones ◽  
Ron Siddle ◽  
...  
Keyword(s):  
Cognitive Behavioural Therapy ◽  
Treatment Method ◽  
Self Esteem ◽  
Behavioural Therapy ◽  
Positive Symptom ◽  
Secondary Outcome ◽  
Symptom Improvement ◽  
Treatment As Usual ◽  
Group Cognitive Behavioural Therapy ◽  
Cognitive Behavioural

BackgroundThe efficacy of cognitive–behavioural therapy for schizophrenia is established, but there is less evidence for a group format.AimsTo evaluate the effectiveness of group cognitive – behavioural therapy for schizophrenia.MethodIn all, 113 people with persistent positive symptoms of schizophrenia were assigned to receive group cognitive – behavioural therapy or treatment as usual. The primary outcome was positive symptom improvement on the Positive and Negative Syndrome Scales. Secondary outcome measures included symptoms, functioning, relapses, hopelessness and self-esteem.ResultsThere were no significant differences between the cognitive-behavioural therapy and treatment as usual on measures of symptoms or functioning or relapse, but group cognitive – behavioural therapy treatment resulted in reductions in feelings of hopelessness and in low self-esteem.ConclusionsAlthough group cognitive – behavioural therapy may not be the optimum treatment method for reducing hallucinations and delusions, it may have important benefits, including feeling less negative about oneself and less hopeless for the future.

scholarly journals Digital cognitive behavioural therapy for insomnia and primary care costs in England: an interrupted time series analysis

BJGP Open ◽  
2021 ◽  
pp. BJGPO.2021.0146
Author(s):  
Chris Sampson ◽  
Eleanor Bell ◽  
Amanda Cole ◽  
Christopher B Miller ◽  
Tracey Marriott ◽  
...  
Keyword(s):  
Primary Care ◽  
Time Series ◽  
Cognitive Behavioural Therapy ◽  
Interrupted Time Series ◽  
Behavioural Therapy ◽  
Interrupted Time Series Analysis ◽  
Cognitive Behavioural ◽  
Before And After ◽  
Quasi Experimental ◽  
Care Costs

BackgroundSleepio is an automated digital programme that delivers cognitive behavioural therapy for insomnia (dCBT-I). Sleepio has been proven effective in improving sleep difficulties. However, evidence for the possible impact of Sleepio use on health care costs in the United Kingdom has not previously been developed.AimWe sought to identify the effect of a population-wide rollout of Sleepio in terms of primary care costs in the National Health Service (NHS) in England.Design & settingThe study was conducted in the Thames Valley region of England, where access to Sleepio was made freely available to all residents between October 2018 and January 2020. The study relies on a quasi-experimental design, using an interrupted time series to compare the trend in primary care costs before and after the rollout of Sleepio.MethodWe use primary care data for people with relevant characteristics from nine general practices in Buckinghamshire. Primary care costs include general practice contacts and prescriptions. Segmented regression analysis was used to estimate primary and secondary outcomes.ResultsFor the 10,704 patients included in our sample, the total saving over the 65-week follow-up period was £71,027. This corresponds to £6.64 per person in our sample or around £70.44 per Sleepio user. Secondary analyses suggest that savings may be driven primarily by reductions in prescribing.ConclusionSleepio rollout reduced primary care costs. National adoption of Sleepio may reduce primary care costs by £20 million in the first year. The expected impact on primary care costs in any particular setting will depend on the uptake of Sleepio.

Cost-effectiveness and cost-utility evaluation of the individual vs. group transdiagnostic psychological treatment for emotional disorders in Primary Care (PsicAP-Costs) v2

2021 ◽  
Author(s):  
Angel Aguilera-Martin ◽  
Mario Gálvez-Lara ◽  
Fátima Cuadrado ◽  
Eliana Moreno ◽  
Francisco García-Torres ◽  
...  
Keyword(s):  
Primary Care ◽  
Cost Effectiveness ◽  
Emotional Disorders ◽  
Cognitive Behavioural Therapy ◽  
Psychological Treatment ◽  
Behavioural Therapy ◽  
Cost Utility ◽  
Cognitive Behavioural ◽  
Utility Evaluation ◽  
The Individual

The aim of this study is to compare, in cost-effectiveness and cost-utility terms, a brief transdiagnostic cognitive-behavioural therapy in two different modes, individual and group, with the treatment usually administered in primary care (TAU). Participants between 18 and 65 years old and with, according to the pretreatment evaluation, mild to moderate emotional disorders will be randomly allocated to the three clusters. They will be assessed again immediately after treatment and 6 and 12 months later. ClinicalTrials.gov: NCT04847310

Sign in / Sign up

Export Citation Format

Share Document